EFFICACY OF SEMAGLUTIDE AND RELATED DRUGS IN ANIMAL MODELS OF VARIOUS DISEASES (AASLD 2026) - Oct 6, 2026 - Abstract #1435; Pres time: Nov 5, 2026; 12:00 PM - 01:00 PM; Location: Convention Center: Poster Hall, Hall DE; " We selected natural occurring obese cynomolgus monkeys to test semaglutide and orforglipron (small molecule GLP-1R agonist)... The weight loss efficacy of semaglutide and other GLP-1R agonists was observed in DIO models in rodents and NHP. In all cases, weight loss was associated with loss of both fat and lean mass. Bimagrumab prevents loss of lean mass without impacting weight loss."
Preclinical • Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Congestive Heart Failure • Diabetes • Fibrosis • Genetic Disorders • Heart Failure • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus
|
|
Yishuang Wei1; Xingjuan Wang2; Ping Chen2; Lingling Chang2; Danyi Zhu2; Chenlin Su2; Ming Ding2; Yunhan Qiu2; Liang Xiang2; Beilei Cai2; Runan Yin2; Xin Li2; Jeff Duan2; Deming Xu1
|